Checkpoint Blockade: Taking a Brake Off a T Cell
Inhibitory receptors that normally limit T-cell responses are used by tumours to avoid killing, and antibodies against those receptors restore it in a minority of patients. This stop covers the mechanism, the markers that predict response, and the autoimmune cost.
What a learner can do afterwards
- Explain how blocking CTLA-4 and blocking PD-1 act at different points of a T-cell response
- Interpret mutational burden and antigen presentation status as predictors of response
- Relate immune-related adverse events to the mechanism of the drug rather than to off-target effects
1 · Read
Some tumours survive by hiding from the T cells built to destroy them. Helpers carry CD4 and coordinate, killers carry CD8 and destroy abnormal cells directly, and regulators calm things so healthy tissue is spared. A naive cell switches on only when it sees its antigen on an MHC molecule plus a second costimulatory push. This is the cell mediated arm of immunity: T cells acting against abnormal cells themselves.
You place the two brakes. CTLA-4 acts early during priming by outcompeting the accelerator CD28 and raising the activation threshold. PD-1 acts later, quieting T cells that already reached the tissue. Blocking CTLA-4 releases the early pool, while blocking PD-1 frees the cells already at the fight.
You compare two patients. One tumour carries many mutations, so its odd neoantigens look foreign and the response is strong once brakes lift. The other hid its presentation machinery, so it stays invisible even with brakes off. You predict the first gains and the second gains little.
You read side effects as mechanism, not poisoning. Released T cells also strike gut, skin, or glands, so inflamed organs follow from the same release that fights the tumour. And you remember the drugs free existing held back cells rather than creating new ones from nothing.
You match the drug to the brake point, you predict response from burden plus presentation, and you treat side effects as on target release.
The rewritten readings were written for this dataset.
More to read
How immune checkpoints limit T cells
Different T cells perform different tasks. CD4 helper cells send signals that organise immune activity. CD8 cytotoxic cells destroy infected or abnormal cells. Regulatory cells restrain responses, protecting healthy tissue. Activating a naive T cell requires recognition of antigen on MHC and a costimulatory signal. Checkpoints limit this activation. CTLA-4 competes with CD28 for binding partners, chiefly restricting initial priming. PD-1 often suppresses activated cells in tissues. These roles overlap rather than forming two fixed stages. Tumours can use checkpoint signals to escape attack. CTLA-4 blockade can strengthen priming; PD-1 blockade can restore activity in suppressed tumour-reactive cells. The treatments therefore influence different, overlapping parts of the response.
Why checkpoint treatment works unevenly
Antigen-presenting cells show pieces of a pathogen to lymphocytes. Cells that recognise those pieces multiply, fight the threat and form a lasting memory population. Recognition depends partly on how unfamiliar the antigens are and how well cells display them. Numerous tumour mutations can generate unfamiliar neoantigens and increase the chance of responding to checkpoint blockade, but do not guarantee success. Tumours with impaired antigen presentation can evade T cells despite treatment. Removing immune restraints can also provoke attacks on healthy tissues, causing inflammation in the gut, skin or glands. These immune-mediated side effects arise from the treatment's intended mechanism, rather than direct drug poisoning.
Checkpoint drugs and adaptive immunity
B cells produce antibodies for humoral immunity, chiefly targeting material outside cells. In cell-mediated immunity, T cells organise responses or destroy abnormal cells. Both branches develop memory, usually making later encounters faster and stronger. Checkpoint treatments act through T cells. They do not manufacture cells, but can reactivate suppressed tumour-reactive cells and support further activation. An existing response can favour improvement, sometimes rapidly. However, a response undetected before treatment does not prove that treatment cannot help.
Explore more
2 · Watch
به انگلیسیTake it off screen
Where it sits
Where this leads
Jobs that lean on this skill. Follow one to see everything it is built on.
8 questions wait behind this lesson, each with its answer explained. Every answer feeds the sky: stars light as they are learned, and dim when it is time to come back.